New pill takes on advanced cancers in early human trial
NCT ID NCT07327294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an early-stage study focused on safety and preliminary effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XNW34017 tablets
What this could lead to
If it works, this could point toward a new oral treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with only 150 participants, so the drug may not shrink tumors or may cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••